Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries



Ferenci, Peter, Bourgeois, Stefan, Buggisch, Peter, Norris, Suzanne, Curescu, Manuela, Larrey, Dominique, Marra, Fiona ORCID: 0000-0003-1326-1149, Kleine, Henning, Dorr, Patrick, Charafeddine, Mariem
et al (show 4 more authors) (2019) Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1-and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. JOURNAL OF VIRAL HEPATITIS, 26 (6). 685 - 696.

[img] Text
Ferenci_et_al-2019-Journal_of_Viral_Hepatitis.pdf - Published Version

Download (594kB) | Preview
Item Type: Article
Uncontrolled Keywords: comorbidity, direct-acting antiviral, drug-drug interaction, hepatitis C virus, real-world evidence
Depositing User: Symplectic Admin
Date Deposited: 04 Jun 2019 09:11
Last Modified: 09 Jan 2021 03:33
DOI: 10.1111/jvh.13080
Open Access URL: http://doi.org/10.1111/jvh.13080
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3044362